LYELHealthcare · BiotechnologyLYEL Stock Forecast: Lyell Immunopharma, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Lyell Immunopharma, Inc. hold a median 12-month price target of $44 — +241.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
LYEL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Lyell Immunopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Volatility (36): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Lyell Immunopharma, Inc. — and when they’d sell — is the membership.
LYEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LYEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +241.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 July 2026 | B. Riley Securities | Initiates | Buy | $44 |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | $34 |
| 15 June 2026 | Needham | Reiterates | Buy | — |
| 15 June 2026 | Needham | Reiterates | Buy | $44 |
| 9 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 8 June 2026 | Needham | Reiterates | Buy | — |
| 8 June 2026 | Needham | Reiterates | Buy | $44 |
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 May 2026 | Needham | Reiterates | Buy | — |
| 10 Apr 2026 | Needham | Initiates | Buy | — |
| 9 Mar 2026 | Citizens | Initiates | Market Outperform | — |
| 9 Dec 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 26 Sept 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 24 June 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LYEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Lyell Immunopharma, Inc. (LYEL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.0×
- Price / sales
- 10228.6×
- Price / book
- 1.1×
- EV / EBITDA
- −0.6×
Cheaper than 82% of US stocks
Cheaper than 1% of US stocks
Cheaper than 69% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- −71.4%
- Earnings growth (YoY)
- −71.4%
- Gross margin
- —
- Operating margin
- −2213050.0%
- Net margin
- 0.0%
Higher than 3% of US stocks
Higher than 6% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
- Return on equity
- −80.8%
- Return on assets
- −29.9%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
LYEL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LYEL appears on the weeks it earns a place.
Frequently asked questions about LYEL stock
What is the LYEL stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Lyell Immunopharma, Inc. have a median 12-month price target of $44, with estimates ranging from $12 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LYEL stock a buy right now?
Of the 7 analysts covering Lyell Immunopharma, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Lyell Immunopharma, Inc. 76 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LYEL?
As at 1 Aug 2026, Lyell Immunopharma, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
Will LYEL stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +241.9% from the last close, and Ticker Nerd's factor model ranks Lyell Immunopharma, Inc. 76 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LYEL stock forecast for 2030?
No analyst covering Lyell Immunopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LYEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $49 over the next 12 months.
How has LYEL stock performed over the past year?
Lyell Immunopharma, Inc. returned +16.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Lyell Immunopharma, Inc. do?
Lyell Immunopharma Inc. is a cutting-edge biotechnology company dedicated to pioneering advancements in cell therapy for cancer treatment.
About Lyell Immunopharma, Inc.
Lyell Immunopharma Inc. is a cutting-edge biotechnology company dedicated to pioneering advancements in cell therapy for cancer treatment. This innovative firm focuses on developing therapeutic platforms aimed at enhancing the functionality of T-cells, a critical component of the body’s immune response against malignancies. Lyell's primary goal is to overcome the limitations of current cell therapies, which often face challenges such as ineffective tumor infiltration and exhaustion of T-cells in challenging tumor microenvironments. The company’s work has significant implications across the healthcare and oncology sectors, potentially transforming the landscape of cancer treatment by providing more effective and personalized therapeutic options. In pursuing scientific breakthroughs, Lyell Immunopharma collaborates with leading researchers and institutions, fostering an environment that encourages innovation and discovery. As a player in the rapidly growing field of immunotherapy, Lyell Immunopharma holds a crucial role in the biopharmaceutical market. The firm’s commitment to research and development underscores its potential to provide impactful medical solutions and enhance the efficacy of cell-based therapies in combating cancer, ultimately aiming to improve patient outcomes globally.
CEO Dr. Lynn Seely M.D., Ph.D. · 161 employees · United States · https://www.lyell.com